Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

[1]  Brian Godman,et al.  Ongoing pharmaceutical reforms in France , 2012 .

[2]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[3]  Irving Fisher.  Health systems in transition. , 2010 .

[4]  S. Williamson.  Patient access schemes for high-cost cancer medicines. , 2010, The Lancet. Oncology.

[5]  Yoav Ben-Shlomo,et al.  Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator , 2009, BMJ : British Medical Journal.

[6]  Jing Jing Li,et al.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. , 2009, JAMA.

[7]  B. Wettermark,et al.  Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future , 2009, Expert review of pharmacoeconomics & outcomes research.

[8]  B. Wettermark,et al.  Soft regulations in pharmaceutical policy making , 2009, Applied health economics and health policy.

[9]  M. White,et al.  Impact of better adherence to statin agents in the primary prevention of coronary artery disease , 2009, European Journal of Clinical Pharmacology.

[10]  A. M. Menti,et al.  The Italian Horizon Scanning Project , 2009, European Journal of Clinical Pharmacology.

[11]  J. Robertson,et al.  Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. , 2009, Australian health review : a publication of the Australian Hospital Association.

[12]  J. Karnon,et al.  Informing disinvestment through cost-effectiveness modelling , 2009 .

[13]  A. Haycox,et al.  Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance , 2009, Expert review of pharmacoeconomics & outcomes research.

[14]  A. Jirillo,et al.  Bevacizumab in advanced cancer, too much or too little? , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  N. Grandfils.  Drug price setting and regulation in France , 2008 .

[16]  A. Haycox,et al.  Enhancing the rational use of new medicines across European health care systems , 2008, European Journal of Clinical Pharmacology.

[17]  A. Haycox,et al.  Insight into recent reforms and initiatives in Austria: implications for key stakeholders , 2008, Expert review of pharmacoeconomics & outcomes research.

[18]  E. Emanuel,et al.  Tier 4 drugs and the fraying of the social compact. , 2008, The New England journal of medicine.

[19]  Jl Carapinha.  Setting the stage for risk-sharing agreements: International experiences and outcomes-based reimbursement , 2008 .

[20]  T. Walley,et al.  Risk Sharing and Payment by Results , 2008, Clinical pharmacology and therapeutics.

[21]  N. Motterlini,et al.  Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. , 2008, Health policy.

[22]  Andrew Jack,et al.  Balancing Big Pharma’s books , 2008, BMJ : British Medical Journal.

[23]  Andrew Briggs,et al.  Value based pricing for NHS drugs: an opportunity not to be missed? , 2008, BMJ : British Medical Journal.

[24]  A Keskinaslan,et al.  The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review , 2007, International journal of clinical practice.

[25]  M. Mcclellan,et al.  Satisfaction guaranteed--"payment by results" for biologic agents. , 2007, The New England journal of medicine.

[26]  S. Garattini,et al.  How can we regulate medicines better? , 2007, BMJ : British Medical Journal.

[27]  Rob Hyde.  Doctors to pay for patients' medicine in Germany , 2007, The Lancet.

[28]  T. Walley.  Fair pricing for medicines in the UK , 2007, Expert review of pharmacoeconomics & outcomes research.

[29]  D. Webb,et al.  Value-based pricing of drugs in the UK , 2007, The Lancet.

[30]  Ann Barrett,et al.  How much will Herceptin really cost? , 2006, BMJ : British Medical Journal.

[31]  A. Pollack.  Genentech caps cost of cancer drug for some patients. , 2006, The New York times on the Web.

[32]  G. Pouvourville.  Risk-sharing agreements for innovative drugs , 2006, The European Journal of Health Economics.

[33]  A. Brower.  'Generic' biotech products: are the floodgates open? At whose expense? , 2006, Biotechnology healthcare.

[34]  G. Apolone,et al.  Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures , 2005, British Journal of Cancer.

[35]  E. Lucchi,et al.  Results of a multi-level therapeutic approach for Alzheimer’s disease subjects in the “real world” (CRONOS project): a 36-week follow-up study , 2005, Aging clinical and experimental research.

[36]  N. Chaudri.  Adherence to Long-term Therapies Evidence for Action , 2004, Annals of Saudi Medicine.

[37]  B. Godman,et al.  Current National Initiatives and Policies to Control Drug Costs in Europe: UK Perspective , 2004, The Journal of ambulatory care management.

[38]  T. Walley,et al.  Neuropsychotherapeutics in the UK , 2004, CNS Drugs.

[39]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[40]  Stephen Chapman,et al.  Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care , 2003, BMJ : British Medical Journal.

[41]  C. Sudlow,et al.  Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis , 2003, BMJ : British Medical Journal.

[42]  Michael O'Brien,et al.  The Day I Died , 2003, BMJ : British Medical Journal.

[43]  A. Guhl.  Pricing and Reimbursement Systems in Europe , 2000, HEPAC Health Economics in Prevention and Care.

[44]  F. Rutten,et al.  No cure, no pay: an acceptable way of financing fertility treatments? , 1989, Health policy.

[45]  No Cure, No Pay , 1886, Hall's journal of health.

[46]  Andrew Briggs,et al.  Access with Evidence Development in the UK , 2012, PharmacoEconomics.

[47]  B. Wettermark,et al.  Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs , 2012, PharmacoEconomics.

[48]  A. Haycox,et al.  Recent National and Regional Drug Reforms in Sweden , 2012, PharmacoEconomics.

[49]  A. Gandjour.  Pharmaceutical Risk-Sharing Agreements , 2012, PharmacoEconomics.

[50]  C. McCabe,et al.  Funding the Unfundable , 2012, PharmacoEconomics.

[51]  Hengjin Dong.  Methods of Economic Evaluation for the German Statutory Healthcare System , 2012, PharmacoEconomics.

[52]  A. Haycox,et al.  Having Your Cake and Eating It , 2012, PharmacoEconomics.

[53]  Sara R. Machado,et al.  Portugal. Health system review. , 2011, Health systems in transition.

[54]  Brian Godman,et al.  Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. , 2010, Applied health economics and health policy.

[55]  Lucero Cahuana-Hurtado,et al.  Health Systems in Transition , 2010 .

[56]  M. Ellis,et al.  Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  U. Tirelli,et al.  Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  P. Kanavos,et al.  Generic medicines from a societal perspective: Savings for health care systems? , 2008 .

[59]  G. de Pouvourville.  Risk-sharing agreements for innovative drugs: a new solution to old problems? , 2006, The European journal of health economics : HEPAC : health economics in prevention and care.

[60]  S. Pegler,et al.  Evaluating promotional material from industry: an evidence-based approach , 2005 .

[61]  Nick Barber,et al.  Concordabe, adherence and Compliance in Medicine Taking , 2005 .

[62]  F. Campana,et al.  Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. , 2004, Archives of gerontology and geriatrics. Supplement.

[63]  S. Chapman,et al.  Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care , 2004 .